Up-to-date List of Nervousness Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Nervousness Medical Research Studies

RankStatusStudy
1 Recruiting Vagotonic Effect of Remifentanil and Autonomic Nervous System Activity.
Conditions: Autonomic Nervous Sytem Activity;   Inluence of Remifentanil on Autonomic Nervous System
Intervention: Drug: Remifentanil
Outcome Measure: Vagomimetic effect of RMFNT in reference to autonomic nervous system activity
2 Recruiting Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Condition: Malignant Solid Tumor - Malignant Nervous System Neoplasm
Intervention: Drug: Cabazitaxel (XRP6258)
Outcome Measures: Maximally tolerated dose of cabazitaxel;   Antitumor activity by evaluating the objective response rate (ORR) for patients with recurrent or refractory high grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG);   Number of adverse events for patients with recurrent or refractory solid tumors including tumors of the central nervous system;   Pharmacokinetics: AUC;   Pharmacokinetics: CL;   Pharmacokinetics: Vss;   Pharmacokinetics: Cmax;   Preliminary anti-tumor activity in patients with recurrent or refractory tumors of the central nervous system;   Progression free survival in patients with recurrent or refractory HGG or DIPG;   Overall survival in patients with recurrent or refractory HGG or DIPG
3 Unknown  Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Condition: Central Nervous System Tumors
Interventions: Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Temozolomide
Outcome Measures: To conduct a phase I study to evaluate the safety of this combination of chemotherapy agents.;   To determine the response of children with recurrent or refractory central nervous system tumors with this combination of chemotherapy agents.;   To compare the response and toxicity with historical controls with the same disease.;   To estimate the 2 and 5 year survival with children treated with this regimen.;   To provide safety and efficacy data for to recommend further larger studies.
4 Recruiting Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Conditions: Brain and Central Nervous System Tumors;   Intraocular Melanoma;   Lung Cancer;   Melanoma (Skin);   Metastatic Cancer;   Neuroblastoma;   Ovarian Cancer;   Retinoblastoma;   Sarcoma;   Small Intestine Cancer
Interventions: Genetic: DNA analysis;   Other: immunologic technique;   Other: pharmacological study;   Radiation: iodine I 131 monoclonal antibody 3F8;   Radiation: 131I-3F8
Outcome Measures: Six-month overall survival;   response rate;   cumulative toxicities
5 Recruiting Rituximab&Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL
Conditions: Primary Central Nervous System Lymphoma;   Brain and Central Nervous System Tumors;   Lymphoma
Interventions: Drug: Rituxan;   Drug: Carboplatin;   Drug: Methotrexate;   Drug: Sodium thiosulfate;   Drug: Neupogen;   Drug: Neulasta;   Drug: Leucovorin
Outcome Measures: Complete response rate;   Overall survival at 2 years;   Event-free survival at 2 years
6 Recruiting MyChoice: An Application of the TFEQ-R18v2
Condition: Central Nervous System Neoplasms
Interventions: Behavioral: Three-Factor Eating Questionnaire (TFEQ)-R18v2;   Behavioral: Multifactor Screener;   Behavioral: Eating Questionnaire-EMA (EQ-EMA)
Outcome Measure: Factor Structure Comparisons of Eating Questionnaires
7 Recruiting The Autonomic Nervous System and Obesity
Conditions: OBESITY;   HYPERTENSION;   PURE AUTONOMIC FAILURE;   SHY-DRAGER SYNDROME
Interventions: Drug: Trimethaphan;   Drug: Pseudoephedrine
Outcome Measures: Change in supine systolic blood pressure after achieving complete ganglionic blockade.;   Change in resting energy expenditure after achieving complete autonomic blockade.
8 Recruiting Alleviating the Metabolic Side Effects of Antipsychotic Medications
Condition: Schizophrenia
Interventions: Drug: Moxonidine;   Drug: Placebo
Outcome Measures: To determine the association between sympathetic nervous system and metabolic abnormalities (eg, weight gain) observed with antipsychotic treatment.;   Change from baseline in sympathetic nervous system activity.
9 Recruiting Longitudinal Study of Biomarkers
Condition: Central Nervous System Tumor
Intervention:
Outcome Measure: Presence of microRNAs and proteins in the blood, cerebrospinal fluid and urine of patients with central nervous system tumors from diagnosis through the course of their treatment
10 Recruiting Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS
Conditions: Multiple Sclerosis;   Autonomic Nervous System
Intervention: Drug: Gilenya
Outcome Measures: RMSSD;   HRV
11 Recruiting Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
Conditions: Childhood Central Nervous System Germ Cell Tumor;   Childhood Central Nervous System Germinoma
Interventions: Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide
Outcome Measures: 3-year PFS rate with NGGCT;   PFS distribution of localized CNS germinoma;   Neurocognitive function using the ALTE07C1 protocol;   Estimation of the PFS distribution of patients with NGGCT treated with IFR;   Estimation of the OS distribution of patients with NGGCT treated with IFR assessed;   Estimation of the PFS distribution of patients with localized germinoma patients and CSF serum hCGβ of 50 mIU/mL or less or CSF serum hCGβ greater than 50 mIU/mL and less than or equal to 100 mIU/mL;   Estimation of the OS distribution of patients with localized germinoma patients and CSF serum hCGβ of 50 mIU/mL or less or CSF serum hCGβ greater than 50 mIU/mL and less than or equal to 100 mIU/mL
12 Recruiting Autonomic Nervous System and Exercise In Gestational Diabetes
Conditions: Gestational Diabetes;   Cardiovascular Risk Factors
Interventions: Other: individual exercise;   Other: general exercise
Outcome Measures: Heart Rate Variability;   VO2max;   autonomic nervous system function;   quality of life;   mental health
13 Recruiting [11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease
Condition: Parkinson's Disease
Intervention: Other: [11C]donepezil PET
Outcome Measure: Distribution volume of [11C]donepezil in internal organs
14 Recruiting Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Conditions: Central Nervous System Disease;   Multiple Sclerosis
Intervention:
Outcome Measures: Diagnostic Study - Definite diagnosis of MS or another disorder. Follow-Up Study - Disease progession as assessed by clinical and MRI criteria.;   Clinical measures of disability (EDSS, NRS, MSFC): MRI measures of lesions and CNS tissue destruction (T2LL, T1LL and calculated black hole fraction, measures of atrophy); and immunological biomarkers.
15 Recruiting The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors
Condition: Radiation Necrosis
Intervention: Drug: Bevacizumab (Avastin®)
Outcome Measures: Feasibility of treating pediatric patients with CNS radiation necrosis with bevacizumab;   Collect multiple aspects of the patient's clinical status and radiologic imaging
16 Recruiting Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
Condition: Radiation Therapy
Intervention:
Outcome Measure:
17 Unknown  Gene-expression Profiles in CNS-metastatic Non-small Cell Lung Cancer
Conditions: Brain Disease;   Metastasis;   Lung Cancer
Intervention:
Outcome Measures: Central nervous system metastasis development;   Death
18 Recruiting Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity
Condition: Metabolic Syndrome
Interventions: Drug: Pioglitazone;   Drug: sugar pill
Outcome Measures: Sympathetic nervous system activity, measured as muscle sympathetic nervous activity and whole-body noradrenaline spillover;   Baroreflex function, adrenoceptor expression
19 Recruiting Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Conditions: Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Lymphoma;   Neurotoxicity;   Radiation Toxicity
Interventions: Biological: rituximab;   Drug: cytarabine;   Drug: methotrexate;   Drug: procarbazine hydrochloride;   Drug: vincristine sulfate;   Radiation: whole-brain radiation therapy
Outcome Measures: Progression free survival (PFS) defined as the interval from randomization to progression or death, whichever occurs first;   Overall survival (OS) defined as the interval from randomization to death due to any cause;   Response rate (partial response or complete response);   Quality of life measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core/Brain Cancer Module (QLQ-C30/BCM20);   Neurocognitive function measured by the Hopkins Verbal Learning Test-Revised (HVLT-R), Trail Making Test Part A, Trail Making Test Part B, Controlled Oral Word Association Test (COWAT)
20 Not yet recruiting Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder (MDD)
Condition: Major Depressive Disorder (MDD)
Interventions: Drug: Agomelatine;   Drug: Escitalopram
Outcome Measures: Change from baseline in markers of sympathetic nervous system activity.;   Change from baseline in the magnitude of morning surge in blood pressure.;   To determine the association between sympathetic nervous system activity and left ventricular hypertrophy.;   Change from baseline in insulin resistance.;   Change from baseline on markers of cardiac risk.

These studies may lead to new treatments and are adding insight into Nervousness etiology and treatment.

A major focus of Nervousness research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Nervousness

© Copyright 2019.

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly. PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.

Privacy | Terms | Contact us